These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11990414)

  • 1. The role of vascular endothelial growth factor in peritoneal hyperpermeability during CAPD-related peritonitis.
    Szeto CC; Wong TY; Lai KB; Chow KM; Li PK
    Perit Dial Int; 2002; 22(2):265-7. PubMed ID: 11990414
    [No Abstract]   [Full Text] [Related]  

  • 2. Growth factors VEGF and TGF-beta1 in peritoneal dialysis.
    Zweers MM; de Waart DR; Smit W; Struijk DG; Krediet RT
    J Lab Clin Med; 1999 Aug; 134(2):124-32. PubMed ID: 10444025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent transforming growth factor-beta 1 expression may predict peritoneal fibrosis in CAPD patients with frequent peritonitis occurrence.
    Lin CY; Chen WP; Yang LY; Chen A; Huang TP
    Am J Nephrol; 1998; 18(6):513-9. PubMed ID: 9845827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peritoneal dialysis effluent, cytokine levels, and peritoneal mesothelial cell viability in CAPD: a possible relationship.
    Carozzi S; Nasini MG; Ravera M; Sanna A; Tirotta A; Lamperi S
    Adv Perit Dial; 1997; 13():7-12. PubMed ID: 9360642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Vascular endothelial growth factor. Its role in peritoneal physiopathology].
    Selgas R; del Peso G; Bajo MA; Cirugeda A; Sánchez-Tomero JA; Alvarez V
    Nefrologia; 2001; 21(5):423-5. PubMed ID: 11795005
    [No Abstract]   [Full Text] [Related]  

  • 6. Persistent transforming growth factor beta 1 expression may predict peritoneal fibrosis in CAPD patients with frequent peritonitis occurrence.
    Lin CY; Chen WP; Fu LW; Yang LY; Huang TP
    Adv Perit Dial; 1997; 13():64-71. PubMed ID: 9360653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions.
    Cooker LA; Luneburg P; Holmes CJ; Jones S; Topley N;
    Perit Dial Int; 2001; 21 Suppl 3():S102-7. PubMed ID: 11887802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selected growth factors in peritoneal dialysis: their relationship to markers of inflammation, dialysis adequacy, residual renal function, and peritoneal membrane transport.
    Stompór T; Zdzienicka A; Motyka M; Dembińska-Kieć A; Davies SJ; Sulowicz W
    Perit Dial Int; 2002; 22(6):670-6. PubMed ID: 12556068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function.
    Margetts PJ; Kolb M; Galt T; Hoff CM; Shockley TR; Gauldie J
    J Am Soc Nephrol; 2001 Oct; 12(10):2029-2039. PubMed ID: 11562401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell populations present in the nocturnal peritoneal effluent of patients on continuous ambulatory peritoneal dialysis and their relationship with peritoneal function and incidence of peritonitis.
    Fernandez de Castro M; Selgas R; Jimenez C; Auxiliadora Bajo M; Martinez V; Romero JR; de Alvaro F; Vara F
    Perit Dial Int; 1994; 14(3):265-70. PubMed ID: 7948240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of intraperitoneal cyclooxygenase inhibition on inflammatory mediators in dialysate and peritoneal membrane characteristics during peritonitis in continuous ambulatory peritoneal dialysis.
    Zemel D; Struijk DG; Dinkla C; Stolk LM; ten Berge IJ; Krediet RT
    J Lab Clin Med; 1995 Aug; 126(2):204-15. PubMed ID: 7636393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor in peritoneal dialysis: a longitudinal follow-up.
    Zweers MM; Struijk DG; Smit W; Krediet RT
    J Lab Clin Med; 2001 Feb; 137(2):125-32. PubMed ID: 11174469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peritoneal permeability and encapsulating peritonitis.
    Verger C; Celicout B
    Lancet; 1985 Apr; 1(8435):986-7. PubMed ID: 2859446
    [No Abstract]   [Full Text] [Related]  

  • 14. Analysis of inflammatory mediators and peritoneal permeability to macromolecules shortly before the onset of overt peritonitis in patients treated with CAPD.
    Zemel D; Betjes MG; Dinkla C; Struijk DG; Krediet RT
    Perit Dial Int; 1995; 15(2):134-41. PubMed ID: 7612733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms of peritoneal permeability--research in growth factors.
    Devuyst O
    Perit Dial Int; 2001; 21 Suppl 3():S19-23. PubMed ID: 11887818
    [No Abstract]   [Full Text] [Related]  

  • 16. Sclerosing encapsulating peritonitis in children.
    Niaudet P; Berard E; Revillon Y; Lothon M; Broyer M
    Contrib Nephrol; 1987; 57():230-8. PubMed ID: 3677698
    [No Abstract]   [Full Text] [Related]  

  • 17. Peritoneal membrane failure as a determinant of the CAPD future. An epidemiological, functional and pathological study.
    Huarte-Loza E; Selgas R; Carmona AR; Martinez ME; Muñoz J; Fontan MP; Ortega O; Escuin F; Sicilia LS
    Contrib Nephrol; 1987; 57():219-29. PubMed ID: 3677696
    [No Abstract]   [Full Text] [Related]  

  • 18. Advanced glycation end-products and peritoneal sclerosis.
    Nakamura S; Niwa T
    Semin Nephrol; 2004 Sep; 24(5):502-5. PubMed ID: 15490420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peritoneal function and peritonitis in patients on peritoneal dialysis.
    Friedlander M
    J Lab Clin Med; 1993 Dec; 122(6):639-40. PubMed ID: 8245682
    [No Abstract]   [Full Text] [Related]  

  • 20. Increased levels of transforming growth factor beta 1 and basic fibroblast growth factor in patients on CAPD: a study during non-infected steady state and peritonitis.
    Mlambo NC; Hylander B; Brauner A
    Inflammation; 1999 Apr; 23(2):131-9. PubMed ID: 10213269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.